Verona Pharma plcVRNA
Market cap
$72.8B
P/E ratio
| Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Product | - | - | - | - | 42 |
| Other revenue | - | - | - | - | 0 |
| Revenues | - | 40 | 0 | - | 42 |
| Cost of sales | - | - | - | - | 3 |
| Research and development | 45 | 79 | 49 | 17 | 45 |
| General and Administrative Expense | 30 | 34 | 27 | 50 | 150 |
| Total operating expenses | 74 | 113 | 76 | 68 | 197 |
| Operating loss | -74 | -73 | -76 | -68 | -155 |
| Research and development tax credit | 8 | 16 | 10 | 1 | 4 |
| Loss on extinguishment of debt | - | - | -1 | - | -4 |
| Interest income | 0 | 0 | 3 | 13 | 15 |
| Interest expense | - | - | - | - | 24 |
| Foreign exchange (loss)/gain | 2 | 0 | -4 | 2 | -0 |
| Total other (expense)/income, net | 9 | 18 | 7 | 14 | -9 |
| Loss before income taxes | -65 | -56 | -68 | -54 | -163 |
| Income tax expense | 0 | -0 | 0 | 0 | 10 |
| Net loss | -65 | -56 | -69 | -54 | -173 |
| Earnings Per Share, Basic | - | - | -0.13 | -0.09 | -0.27 |
| Earnings Per Share, Diluted | - | - | -0.13 | -0.09 | -0.27 |